SG11201509313PA - Thrombin cleavable linker with xten and its uses thereof - Google Patents

Thrombin cleavable linker with xten and its uses thereof

Info

Publication number
SG11201509313PA
SG11201509313PA SG11201509313PA SG11201509313PA SG11201509313PA SG 11201509313P A SG11201509313P A SG 11201509313PA SG 11201509313P A SG11201509313P A SG 11201509313PA SG 11201509313P A SG11201509313P A SG 11201509313PA SG 11201509313P A SG11201509313P A SG 11201509313PA
Authority
SG
Singapore
Prior art keywords
xten
cleavable linker
thrombin cleavable
thrombin
linker
Prior art date
Application number
SG11201509313PA
Other languages
English (en)
Inventor
Ekta Seth Chhabra
John Kulman
Tongyao Liu
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of SG11201509313PA publication Critical patent/SG11201509313PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201509313PA 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof SG11201509313PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840872P 2013-06-28 2013-06-28
PCT/US2014/044731 WO2014210558A1 (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof

Publications (1)

Publication Number Publication Date
SG11201509313PA true SG11201509313PA (en) 2016-01-28

Family

ID=52142742

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201710616XA SG10201710616XA (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof
SG10201913738YA SG10201913738YA (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof
SG11201509313PA SG11201509313PA (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201710616XA SG10201710616XA (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof
SG10201913738YA SG10201913738YA (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof

Country Status (17)

Country Link
US (3) US20160251408A1 (enExample)
EP (2) EP4368194A3 (enExample)
JP (6) JP2016523919A (enExample)
KR (4) KR102714760B1 (enExample)
CN (3) CN105392495A (enExample)
AU (3) AU2014302100B2 (enExample)
CA (1) CA2913078A1 (enExample)
CL (1) CL2015003710A1 (enExample)
EA (1) EA201592022A1 (enExample)
HK (1) HK1223302A1 (enExample)
IL (3) IL242436B (enExample)
MX (1) MX2015016567A (enExample)
NZ (1) NZ713904A (enExample)
PH (1) PH12015502614A1 (enExample)
SG (3) SG10201710616XA (enExample)
TW (3) TWI716340B (enExample)
WO (1) WO2014210558A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
RS59876B1 (sr) * 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
PT4176894T (pt) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
WO2016142289A1 (en) * 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Compounds for improving the half-life of von willebrand factor
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
TW201828975A (zh) * 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
DE3683980D1 (de) 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2003526625A (ja) * 1999-07-23 2003-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血小板の活性化の調節
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
ES2256234T3 (es) 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2479212A1 (en) 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
EP1597279A1 (en) * 2003-02-27 2005-11-23 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
US7807824B2 (en) 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
WO2007021494A2 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
AU2007294805A1 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
WO2008060780A2 (en) 2006-10-04 2008-05-22 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
JP5448839B2 (ja) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
KR20100095441A (ko) * 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
ES2531464T3 (es) * 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
LT2440241T (lt) 2009-06-08 2017-10-10 Amunix Operating Inc. Augimo hormonų polipeptidai ir jų gamybos bei panaudojimo būdai
EP2440228B8 (en) 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
JP5544219B2 (ja) * 2009-09-24 2014-07-09 富士フイルム株式会社 内視鏡システム
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
DK2506868T3 (da) * 2009-12-06 2018-01-29 Bioverativ Therapeutics Inc Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
WO2011084808A2 (en) * 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
DK2591006T3 (da) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
MX369862B (es) * 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
CN104411716B (zh) * 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
RS59876B1 (sr) * 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
ES2657291T3 (es) * 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
PT4176894T (pt) * 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
SG11202010767SA (en) * 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a

Also Published As

Publication number Publication date
SG10201913738YA (en) 2020-03-30
JP2021072853A (ja) 2021-05-13
AU2020203063B2 (en) 2023-05-25
KR102714760B9 (ko) 2025-09-15
KR20160023654A (ko) 2016-03-03
WO2014210558A1 (en) 2014-12-31
CN105392495A (zh) 2016-03-09
JP2019010124A (ja) 2019-01-24
TWI844042B (zh) 2024-06-01
IL266462B (en) 2022-12-01
HK1223302A1 (zh) 2017-07-28
EA201592022A1 (ru) 2016-05-31
CN113817069A (zh) 2021-12-21
KR102714760B1 (ko) 2024-10-11
JP7005800B2 (ja) 2022-02-10
CA2913078A1 (en) 2014-12-31
KR20240023705A (ko) 2024-02-22
CN113831415A (zh) 2021-12-24
IL242436B (en) 2019-05-30
EP3013358A4 (en) 2017-03-22
BR112015031194A2 (pt) 2017-09-19
TWI716340B (zh) 2021-01-21
IL297611B2 (en) 2025-11-01
IL266462B2 (en) 2023-04-01
NZ713904A (en) 2022-02-25
US20160251408A1 (en) 2016-09-01
EP4368194A2 (en) 2024-05-15
TW201514204A (zh) 2015-04-16
PH12015502614A1 (en) 2016-02-29
EP4368194A3 (en) 2024-07-31
TWI770467B (zh) 2022-07-11
AU2014302100B2 (en) 2020-02-13
SG10201710616XA (en) 2018-02-27
KR20230007555A (ko) 2023-01-12
JP2025061316A (ja) 2025-04-10
AU2020203063A1 (en) 2020-05-28
KR20240148954A (ko) 2024-10-11
JP7297837B2 (ja) 2023-06-26
JP7623426B2 (ja) 2025-01-28
AU2023219840A1 (en) 2023-09-14
IL297611A (en) 2022-12-01
TW202313672A (zh) 2023-04-01
KR102865153B1 (ko) 2025-09-29
AU2014302100A1 (en) 2015-11-26
JP2023107932A (ja) 2023-08-03
IL266462A (en) 2019-06-30
TW202045535A (zh) 2020-12-16
JP2016523919A (ja) 2016-08-12
EP3013358A1 (en) 2016-05-04
KR102666819B1 (ko) 2024-05-23
US20240083975A1 (en) 2024-03-14
CL2015003710A1 (es) 2016-08-26
IL297611B1 (en) 2025-07-01
MX2015016567A (es) 2016-03-31
US20220106383A1 (en) 2022-04-07
JP2022000053A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
IL297611B2 (en) A thrombin binder that breaks down with castane and its uses
HUE043851T2 (hu) Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
EP3013347A4 (en) Glycan conjugates and use thereof
IL244744A0 (en) Matrix metalloproteinase-determinable polypeptides and uses thereof
AU2014331645B2 (en) Protein-polymer-drug conjugates
IL241225A0 (en) Plant-based compositions and their uses
PT2877490T (pt) Inteínas clivadas, conjugados e suas utilizações
EP2968561A4 (en) Biophotonic materials and uses thereof
EP2968339A4 (en) Mk2 inhibitors and uses thereof
EP3013359A4 (en) Thrombin cleavable linker
EP3071588A4 (en) Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
EP3087091A4 (en) Var2csa-drug conjugates
EP3039131A4 (en) Enzyme composition and uses thereof
EP2983681A4 (en) Therapeutic compositions and uses thereof
GB201321693D0 (en) Composition and uses thereof
EP3010990A4 (en) Adhesive compositions and use thereof
EP3060724A4 (en) Improvements in and relating to couplers
EP2992334A4 (en) Novel phosphatidylalkanols and compositions thereof
EP3068443A4 (en) Residualizing linkers and uses thereof
HUE069662T2 (hu) Foszforilkolin-konjugátumok és felhasználásuk
TWI562776B (en) Pharmaceutical composition and uses thereof
EP3046929A4 (en) Erk-derived peptides and uses thereof
GB201309178D0 (en) Enzyme and uses thereof
EP2993207A4 (en) Rubber composition and styrene-based resin composition using same
EP2953627A4 (en) NSAIDs DERIVATIVES AND USES THEREOF